USA flag logo/image

An Official Website of the United States Government

Search

Note: The awards database is continually being updated to reflect accurate data as agencies upload their award information

Narrow Search Filters:
Year:2012
Download to spreadsheetPrint
Displaying 5451 – 5475 of 5641 Awards
Company: TYMORA ANALYTICAL OPERATIONS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): With recent technical advances, multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. The vast majority of these signaling pathways involve reversible protein phosphorylation, and the… more
Company: ADVANCED CANCER THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Amongst the different cancer types afflicting the US population, glioblastoma multiforme (GBM) is a dreadful disease with an overall average survival of 10 months. With about 8,000 new cases per year, representing onlyabout 2% of new cancer patients, this disease… more
Company: JBS SCIENCE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): The need to develop an effective method of detecting primary and recurrent hepatocellular carcinoma (HCC) is urgent. HCC is the third leading cause of cancer deaths and has a 5-year survival rate of less than 10%. If HCC is identified early, the survival rate can… more
Company: JBS SCIENCE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Our overall goal is to develop a urine DNA-based screening test for the early detection of colorectal cancer (CRC) that is noninvasive, patient-friendly, and more sensitive than existing noninvasive screening tests. Despite the availability of colonoscopy, the… more
Company: IMCARE BIOTECH Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) and intrahepatic cholagiocarcinoma (ICC) usually go undetected until its late stages, with a 5-year survival rate less than 10%. The survival rate can, however, be as high as 40% ifcancer is detected early. Unfortunately,… more
Company: MARVEL MEDTECH, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Magnetic Resonance Imaging (MRI) of the breast has some clear advantages over traditional breast imaging modalities (x-ray mammography and ultrasound). Breast MRI has been shown to be at least twice as sensitive as mammography or ultrasound in detection of breast… more
Company: STELLA THERAPEUTICS, INC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): There is an urgent need for novel therapies to treat malignant astrocytomas, the most common and aggressive primary tumor of the nervous system. Using current standard of care, patients diagnosed with these tumors havean average life expectancy of 18 months and… more
Company: MedVas Concepts, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): The product that will be developed by MedVas Concepts is a drug targeting vehicle for cancer therapeutics used in combination with radiation therapy. The product uses a feature of ionizing radiation to match drug delivery selectivity with that of the radiation… more
Company: MICROSTEM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Lung cancer remains a leading cause of cancer death worldwide. In the US, lung cancer is responsible for 29% of cancer-related death, more than breast, colon and prostate cancers combined. Current conventional therapy- surgery, chemotherapy, radiotherapy, etc.… more
Company: PENFORGEL, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Better therapies are needed to treat malignant melanoma, the most deadly form of skin cancer. Multiple pathways such as STAT, MAP and PI3 kinase are deregulated in the development of melanoma, and targeting these pathways in melanoma cells, could be used as a… more
Company: RADTARGX THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): The overall objective of this research is to test the hypothesis that monoclonal antibodies to radiation-induced tumor neoantigens cause therapeutically beneficial immune responses in cancer models. We will study the efficacy of a mouse monoclonal antibody to a… more
Company: ENSYSCE BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Ensysce Biosciences Inc. is a biotechnology company located in Houston, TX, exploiting the pionering nanotechnology studies of the late 1996 Nobel Laureate, Dr. Richard Smalley of Rice University. The rights to Dr. Smalley's work on carbon nanotube… more
Company: TUMOREND, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): CM101 is a polysaccharide tumor angiogenesis-targeting, complement activating, immune stimulating biological produced fermentatively from Group B Streptococcus. CM101 binds a capillary endothelium receptor, HP59, causing inflammatory cytokine cascades, recruiting… more
Company: MODULATION THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. A small business, Modulation Therapeutics Incorporated,… more
Company: MODULATION THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi-drug resistant phenotype, contributes to poor clinicaloutcomes. Our laboratory has recently… more
Company: VASGENE THERAPEUTICS, INC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): This is aimed at the pre-clinical development of soluble EphB4-HSA (sEphB4-HSA) and its ultimate commercialization for the treatment of various cancer types. sEphB4-HSA was chosen as a pre-clinical due to better efficacy in direct comparisons in xenograft models.… more
Company: VASGENE THERAPEUTICS, INC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): This is aimed at the pre-clinical development of humanized MAb131 (h131) and its ultimate commercialization for the treatment of various cancer types. H131 was chosen for its ability to induce receptor endocytosis, degradation, and inhibition of endothelial cell… more
Company: BENEVIR BIOPHARM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Oncolytic virus (OV) therapies for cancer employ a dual mechanism of action and have two major advantages. First, OV are attenuated and designed to efficiently replicate in and kill only cancer cells, creating a largesafety profile. Second, as observed in animal… more
Company: BENEVIR BIOPHARM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: There are ~20,000 cases per year of glioblastoma in the U.S., and median survival time is only 15 months. The integration of two technologies to create an optimized oncolytic virus for glioblastoma is proposed. The resulting virus is triply armed: (1) it has a clinically proven mechanism and… more
Company: SHARP EDGE LABS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): This SBIR Phase I project involves the creation of a new fluorogenic detection platform compatible with point-of-care instrumentation, enabling more information-rich biomarkers to be deployed in the coming era of personalized medicine. Current methods for… more
Company: DELPHINUS MEDICAL TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Ultrasound tomography is an emerging modality for breast imaging. However, current ultrasonic tomography's imaging algorithms, hindered by the limited memory and processor speed of computers, are based on ray theory andassume a homogeneous background, which… more
Company: DELPHINUS MEDICAL TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Mammography is the current cost-effective gold standard for breast cancer screening. However, its usefulness has recently become a subject of considerable debate. The limitations of mammography are most evident in the population of women who have dense breast… more
Company: NANOHYBRIDS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): In the last decade, combined ultrasound and photoacoustic (USPA) imaging - a synergistic and complementary combination of two ultrasound-based techniques, has been introduced and is now gaining wide acceptance in both pre-clinical and clinical arenas. USPA is… more
Company: AURORA ONCOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Bladder cancer is the 4th most common cancer in the U.S. Accounting For ~70,000 new cases annually and ~15,000 deaths. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in about40% of cases with recurrences that… more
Company: TOCAGEN, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Many strategies for gene therapy of solid tumors involve the use of replication-defective Moloney murine leukemia (MLV)-based retroviral vectors, but efficacy has been limited due to lack of adequate tumor transduction.Gene transfer using replication-competent… more
Displaying 5451 – 5475 of 5641 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.